New antibiotic under the microscope: can it beat superbug infections?
NCT ID NCT07601711
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is observing 200 hospitalized adults with carbapenem-resistant Acinetobacter baumannii (CRAB) infections—a type of superbug—who are treated with the antibiotic sulbactam-durlobactam. Researchers will compare their outcomes to patients receiving other treatments to see if the new drug is more effective and safe. The goal is to gather real-world evidence to guide better treatment decisions for these serious infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLOODSTREAM INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sichuan Provincial People's Hospital
RECRUITINGChengdu, Sichuan, 610072, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we optimize antibiotic dosing for children with sepsis?
- Could starting feeds sooner shield preterm babies from infection?
- AI could outsmart bacteria: a smarter way to choose antibiotics?
- Can brain waves predict thinking problems after sepsis?
- Breathing technique may outperform spirometry for smog pneumonia recovery
- A gentle touch against coughs and colds: could manual therapy shorten respiratory illness?